Melanoma International Collaboration for Adaptive Trials (MICAT)

Transforming the development of melanoma therapies

What if there was a better way to do drug research…

AIM’s Melanoma International Collaboration for Adaptive Trials (MICAT) wants to change the way we conduct melanoma clinical trials. We need to find answers faster, with greater precision, so that more patients can be successfully treated.

A smarter approach to drug research

MICAT uses an adaptive trial design to test new drugs on patients whose previously treated melanoma has spread. Rather than testing one drug at a time vs. the standard of care, MICAT simultaneously investigates multiple treatments using fewer patients by relying on dynamic data analysis to drive design in real time. MICAT will get the right drug to the right patient at the right time—and MICAT will do this faster than traditional clinical trials do.

Faster answers for tough questions

The stakes are high so we set the bar even higher. MICAT is working to discover:

  • How to match the right treatment to the right patient
  • What treatments are most likely to increase survival
  • Which treatments should be used first? Second? Third?
  • How biomarkers can guide treatment options

Combining forces to forge change

This is a group effort. AIM has brought together academic, regulatory, and industry partners to accelerate the approval of effective melanoma treatments.

  • AIM at Melanoma
  • IMWG (International Melanoma Working Group, an initiative of AIM)
  • Pharmaceutical Product Development, LLC
  • Berry Consultants
  • RA Capital
  • Industry partners

How you can help

MICAT is seeking support for this groundbreaking crusade to a CURE. To learn how you can help transform the discovery of effective treatments, contact Alicia Rowell, Vice President, AIM at Melanoma at

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.